In conclusion, the results suggest that the detection of polymorphisms in the GSTP1, ITGA4, NQO1, AKT1, GP6, ZMIZ1, ADA, and NOX3 genes may be used in the future as a predictive marker of treatment response with new therapies in patients diagnosed with MS. The gene discussed is GP6; the disease is myeloid sarcoma.